Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Vasomune Therapeutics has brought together decades of academic research to create a clinical-stage candidate for the treatment of diseases associated with vascular dysfunction, particularly pathogen-induced acute respiratory-distress syndrome.
By coupling its expertise, scale, and technologies with those of like-minded biopharma partners GSK is striving to make a real difference for patients.
Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis develops predictive biomarkers to guide treatment decisions. The company’s next-generation biomarkers work for real patients by informing targeted treatment decisions for better outcomes.
The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.
Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.
Venture-backed start-up MeCo Diagnostics has developed a first-in-class, clinically validated, prognostic and predictive biomarker test to enable targeted antifibrotic therapy for early-stage breast cancer patients.
Cognigenics is using advanced gene-editing techniques to develop intranasal treatments that target neural networks associated with anxiety and memory disorders, which could yield long-term solutions.
Combining first-in-class delivery and engineering tools, Ensoma is developing one-time in vivo treatments that can precisely engineer any cell of the blood and immune systems to cure diseases from within.
JCR Pharmaceuticals’ unique brain-shuttling technology opens new treatment opportunities for meeting the needs of patients grappling with CNS diseases.
By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.
Based on advances in the understanding of the etiology of neurodegeneration, SciNeuro Pharmaceuticals is developing ground-breaking therapies with multi-indication potential.
Approaches to slow or reverse aging have gained momentum in recent years, but the field is still in its infancy with hurdles to overcome, as illustrated by efforts to develop therapies that clear senescent cells.
